Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin

Patrizia Gazzerro, Anna M. Malfitano, Maria Chiara Proto, Antonietta Santoro, Simona Pisanti, Maria Gabriella Caruso, Maria Notarnicola, Caterina Messa, Chiara Laezza, Gabriella Misso, Michele Caraglia, Maurizio Bifulco

Research output: Contribution to journalArticle

Abstract

Rimonabant (SR141716), a highly selective cannabinoid receptor antagonist, exerts along with its anti-obesity action, pleiotropic functions affecting a broad range of diseases, from obesity-related co-morbidities to drug dependence and cancer. Several studies suggested an anti-tumour activity of rimonabant in several in vitro and in vivo models. In this study, we compared the anti-proliferative effect of SR141716 in the human colon cancer cell line DLD-1 with oxaliplatin, one of the cytotoxic drugs currently used in the treatment of colorectal cancer. We show that SR141716 inhibits DLD-1 cell proliferation similarly to oxaliplatin and if administered in combination SR141716 potentiated the inhibitory effect caused by oxaliplatin. Assessment of drug interaction was performed calculating combination index that showed a strong synergistic effect between the two drugs added to cells in combination. Our findings suggest that the combined synergic effect of SR141716 and oxaliplatin improves the blocking of colon cancer cell proliferation. Therefore, this combination merits further explorations in preclinical and clinical settings.

Original languageEnglish
Pages (from-to)171-175
Number of pages5
JournalOncology Reports
Volume23
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

oxaliplatin
rimonabant
Cannabinoid Receptor Antagonists
Colonic Neoplasms
Growth
Obesity
Cell Proliferation
Inhibition (Psychology)
Drug Interactions
Pharmaceutical Preparations
Substance-Related Disorders
Colorectal Neoplasms

Keywords

  • Cannabinoid receptor
  • Colon
  • Combinatory analysis
  • Oxaliplatin
  • Rimonabant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. / Gazzerro, Patrizia; Malfitano, Anna M.; Proto, Maria Chiara; Santoro, Antonietta; Pisanti, Simona; Caruso, Maria Gabriella; Notarnicola, Maria; Messa, Caterina; Laezza, Chiara; Misso, Gabriella; Caraglia, Michele; Bifulco, Maurizio.

In: Oncology Reports, Vol. 23, No. 1, 2010, p. 171-175.

Research output: Contribution to journalArticle

Gazzerro, P, Malfitano, AM, Proto, MC, Santoro, A, Pisanti, S, Caruso, MG, Notarnicola, M, Messa, C, Laezza, C, Misso, G, Caraglia, M & Bifulco, M 2010, 'Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin', Oncology Reports, vol. 23, no. 1, pp. 171-175. https://doi.org/10.3892/or-00000619
Gazzerro, Patrizia ; Malfitano, Anna M. ; Proto, Maria Chiara ; Santoro, Antonietta ; Pisanti, Simona ; Caruso, Maria Gabriella ; Notarnicola, Maria ; Messa, Caterina ; Laezza, Chiara ; Misso, Gabriella ; Caraglia, Michele ; Bifulco, Maurizio. / Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. In: Oncology Reports. 2010 ; Vol. 23, No. 1. pp. 171-175.
@article{8071fba9777043e4b58d447ddd4b5d9d,
title = "Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin",
abstract = "Rimonabant (SR141716), a highly selective cannabinoid receptor antagonist, exerts along with its anti-obesity action, pleiotropic functions affecting a broad range of diseases, from obesity-related co-morbidities to drug dependence and cancer. Several studies suggested an anti-tumour activity of rimonabant in several in vitro and in vivo models. In this study, we compared the anti-proliferative effect of SR141716 in the human colon cancer cell line DLD-1 with oxaliplatin, one of the cytotoxic drugs currently used in the treatment of colorectal cancer. We show that SR141716 inhibits DLD-1 cell proliferation similarly to oxaliplatin and if administered in combination SR141716 potentiated the inhibitory effect caused by oxaliplatin. Assessment of drug interaction was performed calculating combination index that showed a strong synergistic effect between the two drugs added to cells in combination. Our findings suggest that the combined synergic effect of SR141716 and oxaliplatin improves the blocking of colon cancer cell proliferation. Therefore, this combination merits further explorations in preclinical and clinical settings.",
keywords = "Cannabinoid receptor, Colon, Combinatory analysis, Oxaliplatin, Rimonabant",
author = "Patrizia Gazzerro and Malfitano, {Anna M.} and Proto, {Maria Chiara} and Antonietta Santoro and Simona Pisanti and Caruso, {Maria Gabriella} and Maria Notarnicola and Caterina Messa and Chiara Laezza and Gabriella Misso and Michele Caraglia and Maurizio Bifulco",
year = "2010",
doi = "10.3892/or-00000619",
language = "English",
volume = "23",
pages = "171--175",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin

AU - Gazzerro, Patrizia

AU - Malfitano, Anna M.

AU - Proto, Maria Chiara

AU - Santoro, Antonietta

AU - Pisanti, Simona

AU - Caruso, Maria Gabriella

AU - Notarnicola, Maria

AU - Messa, Caterina

AU - Laezza, Chiara

AU - Misso, Gabriella

AU - Caraglia, Michele

AU - Bifulco, Maurizio

PY - 2010

Y1 - 2010

N2 - Rimonabant (SR141716), a highly selective cannabinoid receptor antagonist, exerts along with its anti-obesity action, pleiotropic functions affecting a broad range of diseases, from obesity-related co-morbidities to drug dependence and cancer. Several studies suggested an anti-tumour activity of rimonabant in several in vitro and in vivo models. In this study, we compared the anti-proliferative effect of SR141716 in the human colon cancer cell line DLD-1 with oxaliplatin, one of the cytotoxic drugs currently used in the treatment of colorectal cancer. We show that SR141716 inhibits DLD-1 cell proliferation similarly to oxaliplatin and if administered in combination SR141716 potentiated the inhibitory effect caused by oxaliplatin. Assessment of drug interaction was performed calculating combination index that showed a strong synergistic effect between the two drugs added to cells in combination. Our findings suggest that the combined synergic effect of SR141716 and oxaliplatin improves the blocking of colon cancer cell proliferation. Therefore, this combination merits further explorations in preclinical and clinical settings.

AB - Rimonabant (SR141716), a highly selective cannabinoid receptor antagonist, exerts along with its anti-obesity action, pleiotropic functions affecting a broad range of diseases, from obesity-related co-morbidities to drug dependence and cancer. Several studies suggested an anti-tumour activity of rimonabant in several in vitro and in vivo models. In this study, we compared the anti-proliferative effect of SR141716 in the human colon cancer cell line DLD-1 with oxaliplatin, one of the cytotoxic drugs currently used in the treatment of colorectal cancer. We show that SR141716 inhibits DLD-1 cell proliferation similarly to oxaliplatin and if administered in combination SR141716 potentiated the inhibitory effect caused by oxaliplatin. Assessment of drug interaction was performed calculating combination index that showed a strong synergistic effect between the two drugs added to cells in combination. Our findings suggest that the combined synergic effect of SR141716 and oxaliplatin improves the blocking of colon cancer cell proliferation. Therefore, this combination merits further explorations in preclinical and clinical settings.

KW - Cannabinoid receptor

KW - Colon

KW - Combinatory analysis

KW - Oxaliplatin

KW - Rimonabant

UR - http://www.scopus.com/inward/record.url?scp=76049105445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049105445&partnerID=8YFLogxK

U2 - 10.3892/or-00000619

DO - 10.3892/or-00000619

M3 - Article

C2 - 19956878

AN - SCOPUS:76049105445

VL - 23

SP - 171

EP - 175

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -